Akari Therapeutics (NASDAQ:AKTX – Get Free Report) and WAVE Life Sciences (NASDAQ:WVE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.
Profitability
This table compares Akari Therapeutics and WAVE Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akari Therapeutics | N/A | -123.29% | -63.01% |
| WAVE Life Sciences | -255.70% | -56.76% | -42.80% |
Analyst Recommendations
This is a breakdown of recent ratings for Akari Therapeutics and WAVE Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akari Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| WAVE Life Sciences | 1 | 0 | 14 | 0 | 2.87 |
Insider & Institutional Ownership
5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Akari Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the S&P 500.
Earnings and Valuation
This table compares Akari Therapeutics and WAVE Life Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akari Therapeutics | N/A | N/A | -$17.30 million | N/A | N/A |
| WAVE Life Sciences | $42.73 million | 25.94 | -$204.38 million | ($1.06) | -5.43 |
Akari Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences.
Summary
WAVE Life Sciences beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
About WAVE Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
